Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. (Q30422022)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

neurofibromatosis type II

2 March 2020

main subject

1 reference

inferred from title

author

Matthias A. Karajannis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Anna Y Derman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Judith D. Goldberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jeffrey H. Wisoff

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jeffrey Allen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Geneviève Legault

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Mari Hagiwara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Filippo G Giancotti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alexander Filatov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Tsivia Hochman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Emilio Vega

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

John G Golfinos

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Amanda Merkelson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

J Thomas Roland

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

4 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

292-297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome

2 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Everolimus for advanced pancreatic neuroendocrine tumors.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

mTOR: from growth signal integration to cancer, diabetes and ageing

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Targeting mTOR in renal cell carcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

The natural history of vestibular schwannoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

TOR signaling in growth and metabolism

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Systematic review of the natural history of vestibular schwannoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Clinical pharmacokinetics of everolimus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Optimal two-stage designs for phase II clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Speech-discrimination scores modeled as a binomial variable.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

A qualitative study of the impact of living with neurofibromatosis type 2.

20 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Phase I study of everolimus in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Using audiometric thresholds and word recognition in a treatment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT150

Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3895376

Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24311643

12 December 2020

inferred from PubMed ID database lookup

The Natural History of Vestibular Schwannoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24311643

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1093/NEUONC/NOT150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

release_tncpkrgc6zdetit6zoh2ynjhsi

2 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tncpkrgc6zdetit6zoh2ynjhsi

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24311643%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference